Stocktoria
AstraZeneca PLC AZN.L
AstraZeneca PLC (AZN.L) earns a Piotroski F-score of 8/9 (strong financial health), with an Altman Z″ in the grey zone. It pays a dividend yielding 2.27% (safety: moderate). FY2025 revenue was $58.7B at a 17.4% net margin.
Price from month-end closes (Yahoo) — for reference, not real-time.
How it ranks in Healthcare · percentile among 23 companies
Percentile vs other Healthcare companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 8/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | -0.017 |
| Retained earnings / assets | 0.096 |
| EBIT / assets | 0.117 |
| Equity / liabilities | 0.745 |
FAQ
Is AZN.L financially healthy?
AstraZeneca PLC's Piotroski F-score is 8/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does AZN.L pay a dividend, and is it safe?
Yes. AstraZeneca PLC pays a dividend yielding about 2.27% with a 48.6% payout ratio, rated “moderate” for safety.
How profitable is AZN.L?
In FY2025, AstraZeneca PLC had a net margin of 17.4% and a return on equity of 21.0%.
Source: company filings via Yahoo Finance · GB · as of 2025-12-31. Figures in GBp; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.